AstraZeneca makes another obesity play funnelling $80m into SixPeaks Bio
AstraZeneca has the option to acquire SixPeaks in the next two years if the latter’s bispecific antibody proves successful.
AstraZeneca has the option to acquire SixPeaks in the next two years if the latter’s bispecific antibody proves successful.
What's Your Reaction?
